Reversal of multidrug resistance by magnetic Fe₃O₄ nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells

Original Research

(5980) Total Article Views

Authors: Bao-an Chen, Pei-pei Mao, Jian Cheng, et al

Published Date June 2010 Volume 2010:5 Pages 437 - 444

DOI: http://dx.doi.org/10.2147/IJN.S10083

Bao-an Chen¹, Pei-pei Mao¹, Jian Cheng¹, Feng Gao¹, Guo-hua Xia¹, Wen-lin Xu², Hui-lin Shen², Jia-hua Ding¹, Chong Gao¹, Qian Sun¹, Wen-ji Chen¹, Ning-na Chen¹, Li-jie Liu³, Xiao-mao Li⁴, Xue-mei Wang⁵

¹Department of Hematology, The Affiliated Zhongda Hospital, Clinical Medical School, Southeast University, Nanjing, People’s Republic of China; ²Department of Hematology, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, People’s Republic of China; ³Institution of Physiology, Southeast University, Nanjing, People’s Republic of China; ⁴Department of Physics, University of Saarland, Saarbruecken, Germany; ⁵State Key Lab of Bioelectronics (Chien-Shiung Wu Laboratory), Southeast University, Nanjing, People’s Republic of China

Abstract: In many instances, multidrug resistance (MDR) is mediated by increasing the expression at the cell surface of the MDR1 gene product, P-glycoprotein (P-gp), a 170-kD energy-dependent efflux pump. The aim of this study was to investigate the potential benefit of combination therapy with magnetic Fe₃O₄ nanoparticle [MNP (Fe₃O₄)] and MDR1 shRNA expression vector in K562/A02 cells. For stable reversal of “classical” MDR by short hairpin RNA (shRNA) aiming directly at the target sequence (3491–3509, 1539–1557, and 3103–3121 nucleotide) of MDR1 mRNA. PGC silencer-U6-neo-GFP-shRNA/MDR1 called PGY1–1, PGY1–2, and PGY1–3 were constructed and transfected into K562/A02 cells by lipofectamine 2000. After transfected and incubated with or without MNP (Fe₃O₄) for 48 hours, the transcription of MDR1 mRNA and the expression of P-gp were detected by quantitative real-time PCR and Western-blot assay respectively. Meanwhile intracellular concentration of DNR in K562/A02 cells was detected by flow cytometry (FCM). PGC silencer-U6-neo-GFP-shRNA/MDR1 was successfully constructed, which was confirmed by sequencing and PGY1–2 had the greatest MDR1 gene inhibitory ratio. Analysis of the reversal ratio of MDR, the concentration of daunorubicin (DNR) and the transcription of MDR1 gene and expression of P-gp in K562/A02 showed that combination of DNR with either MNP (Fe₃O₄) or PGY1–2 exerted a potent cytotoxic effect on K562/A02 cells, while combination of MNP (Fe₃O₄) and PGY1–2 could synergistically reverse multidrug resistance. Thus our in vitro data strongly suggested that a combination of MNP (Fe₃O₄) and shRNA expression vector might be a more sufficient and less toxic anti-MDR method on leukemia.

Keywords: K562/A02 cell line, multidrug resistance, magnetic nanoparticle of Fe₃O₄, recombinant plasmid vector PGY1–2

Other articles by Professor Baoan Chen

Readers of this article also read: